HISTONES AND/OR proADM AS MARKERS INDICATING ADVERSE EVENT Russian patent published in 2022 - IPC G01N33/68 A61B5/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and concerns a method for predicting the death of a subject with a critical illness, wherein the specified method includes (i) determining the level of at least one histone in a sample from the specified subject, while the specified level of at least one histone indicates the specified death in the specified subject; and (ii) determining the level of proadrenomedulline (hereinafter – proADM) in the sample from the specified subject, while the specified level of proADM indicates the specified death in the specified subject, and where the specified level of at least one histone and the specified level of proADM indicate death within the next 28 days, while the specified sample is blood, blood plasma, blood serum or urine. The group of inventions also concerns a kit for implementing the specified method, wherein the specified kit includes (i) reagents for determining the level of at least one histone in the specified sample of the specified subject and control data, including the control level of at least one histone; and (ii) reagents for determining the level of proADM in the specified sample of the specified subject and control data, including the control level of proADM; the application of the kit for predicting the subject’s death.

EFFECT: group of inventions provides prediction of the subject’s death.

9 cl, 1 ex, 6 tbl